Difference between revisions of "Leuprolide (Lupron)"
Jump to navigation
Jump to search
(updated content) |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.rxabbvie.com/pdf/ | + | Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.rxabbvie.com/pdf/lupronuro_pi.pdf Leuprolide (Lupron) package insert]</ref><ref>[[Media:Leuprolidelupron.pdf|Leuprolide (Lupron) package insert (locally hosted backup)]]</ref><ref>[http://www.lupron.com/ Lupron manufacturer's website]</ref><ref name="Eligard">[http://products.sanofi.us/eligard/eligard.pdf Leuprolide (Eligard) package insert]</ref><ref>[[Media:Leuprolideeligard.pdf|Leuprolide (Eligard) package insert (locally hosted backup)]]</ref><ref>[http://www.eligard.com Eligard manufacturer's website]</ref> |
<br>Route: IM | <br>Route: IM | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| Line 13: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/chemotherapy/drug-info/Leuprolide.aspx Leuprolide (Lupron) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Leuprolide.aspx Leuprolide (Lupron) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/Leuprolide.aspx Leuprolide (Lupron) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/Leuprolide.aspx Leuprolide (Lupron) patient drug information (Chemocare)]</ref> | ||
| − | *Brief patient counseling information can be found | + | *Brief patient counseling information can be found in the [http://www.rxabbvie.com/pdf/lupronuro_pi.pdf Leuprolide (Lupron) package insert]<ref name="insert"></ref> |
| + | *Brief patient counseling information can be found in the [http://products.sanofi.us/eligard/eligard.pdf Leuprolide (Eligard) package insert]<ref name="Eligard"></ref> | ||
*[http://www.uptodate.com/contents/leuprolide-patient-drug-information Leuprolide (Lupron) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/leuprolide-patient-drug-information Leuprolide (Lupron) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/leuprolide-patient-drug-information Leuprolide (Lupron) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/leuprolide-patient-drug-information Leuprolide (Lupron) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *4/09/1985: Initial FDA approval for palliative treatment of advanced prostate cancer. | ||
| + | |||
| + | ==Also known as== | ||
| + | Eligard, leuprolide acetate, Lupron Depot, Leupromer, Leuprorelin, Prostap SR, Prostap 3, or Viadur. | ||
==References== | ==References== | ||
Revision as of 08:10, 20 November 2014
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2][3][4][5][6]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Leuprolide (Lupron) patient drug information (Chemocare)[7]
- Brief patient counseling information can be found in the Leuprolide (Lupron) package insert[1]
- Brief patient counseling information can be found in the Leuprolide (Eligard) package insert[4]
- Leuprolide (Lupron) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 4/09/1985: Initial FDA approval for palliative treatment of advanced prostate cancer.
Also known as
Eligard, leuprolide acetate, Lupron Depot, Leupromer, Leuprorelin, Prostap SR, Prostap 3, or Viadur.
References
- ↑ 1.0 1.1 1.2 Leuprolide (Lupron) package insert
- ↑ Leuprolide (Lupron) package insert (locally hosted backup)
- ↑ Lupron manufacturer's website
- ↑ 4.0 4.1 Leuprolide (Eligard) package insert
- ↑ Leuprolide (Eligard) package insert (locally hosted backup)
- ↑ Eligard manufacturer's website
- ↑ Leuprolide (Lupron) patient drug information (Chemocare)
- ↑ Leuprolide (Lupron) patient drug information (UpToDate)